Endoscopic Retrograde Cholangiopancreatography Devices Market Size, Share, and Trends Analysis - Global - 2025-2032 - Includes: Sphincterotome Market, Bilary Stone Removal Balloon Market, and 6 more
Description
Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Device Market Report, 2025 Edition
Executive Summary
The global endoscopic retrograde cholangiopancreatography (ERCP) device market was valued at over $1.9 billion in 2025. The market is projected to grow at a compound annual growth rate (CAGR) of 5.6%, reaching over $2.8 billion by 2032.
This report covers sphincterotomes, biliary stone removal balloons, biliary stone removal baskets, biliary dilation balloons, biliary and pancreatic stents, biliary lithotripters, ERCP guidewires, and ERCP cannulas.
It quantifies unit sales, average selling prices (ASPs), market values, and growth rates, and includes company shares, market drivers and limiters, recent mergers and acquisitions, and technology trends. The analysis incorporates historical data from 2022 to 2024 and forecasts through 2032.
The scope reflects how healthcare providers are adopting minimally invasive, therapeutic ERCP techniques and how ongoing product innovation, particularly short-wire systems and lumen-apposing stents, is improving procedural efficiency and patient outcomes.
Market Overview
Endoscopic retrograde cholangiopancreatography (ERCP) is a specialized endoscopic procedure used to diagnose and treat conditions of the biliary and pancreatic ducts. It combines endoscopic and fluoroscopic imaging to enable interventions such as sphincterotomy, stone extraction, and stent placement.
Over the past decade, the role of ERCP has evolved from a primarily diagnostic tool to a therapeutic intervention, supported by major advances in device design and procedural technique. This transformation has expanded the addressable market for ERCP devices and positioned the field as a cornerstone of minimally invasive gastrointestinal care.
Market growth is being driven by increasing procedure volumes in both developed and emerging regions. The rising global incidence of biliary obstruction, gallstones, and pancreatitis is fueling demand for ERCP interventions. As populations age and chronic liver diseases become more prevalent, procedure frequency continues to rise.
Technology innovation has been especially impactful in improving physician control and reducing complication rates. The introduction of short-wire systems allows for faster cannulation, enhanced device exchange, and more efficient workflow. These systems are now regarded as the new procedural standard in many high-volume centers.
Drug-eluting and lumen-apposing stent technologies are also expanding the therapeutic capabilities of ERCP, enabling the management of complex indications such as pancreatic fluid collections and walled-off necrosis under endoscopic ultrasound (EUS) guidance.
At the same time, certain segments such as ERCP cannulas are gradually being replaced by more advanced device types like sphincterotomes, limiting growth in specific categories. Despite these internal shifts, the ERCP device market remains positioned for sustained expansion through the next decade, reflecting both strong procedural momentum and the integration of therapeutic endoscopy into routine care.
Market Drivers
Sphincterotome Market
The shift toward therapeutic ERCP is a primary growth driver for the global market. As procedures increasingly focus on intervention rather than diagnosis, sphincterotomes are seeing rising demand. This segment represents one of the largest portions of the ERCP device market and will continue to influence overall growth through 2032.
Advancements in sphincterotome design, such as improved wire control and compatibility with short-wire systems, are further expanding utilization. As hospitals transition toward single-use accessories to reduce infection risk, this category’s contribution to overall market value is expected to strengthen.
Short-Wire Systems
The increasing use of short-wire systems is reshaping how ERCP procedures are performed. These systems provide physicians with greater procedural control and efficiency while reducing the need for an assistant during cannulation and device exchange.
Short-wire configurations are more expensive than traditional long-wire systems but offer clinical and operational advantages that justify the premium. Adoption is accelerating in both hospital and ambulatory endoscopy settings, where shorter procedure times improve throughput and reduce anesthesia exposure. As a result, short-wire systems are contributing to rising ASPs and overall revenue growth.
Physician Familiarity and Training
As endoscopists gain more experience and training in therapeutic ERCP, procedural confidence is improving. The rise in physician familiarity has directly translated into higher case volumes per practitioner. Medical societies and device manufacturers are expanding training programs, increasing comfort with advanced ERCP techniques such as sphincterotomy, stenting, and lithotripsy.
These trends are particularly important in emerging markets, where expanded access to training and fluoroscopy equipment is helping to increase the number of qualified providers capable of performing ERCP safely and effectively.
Market Limiters
Cannula Market Decline
The ERCP cannula segment is being steadily replaced by sphincterotome-based techniques. Cannulas once represented a standard access tool but are now losing share as more efficient alternatives become the norm. As a result, unit sales have stagnated and average selling prices have declined for several years. Manufacturers have reduced pricing to remain competitive, suppressing total market value growth.
This structural change is expected to continue until cannulas are fully phased out, reinforcing the dominance of sphincterotome-guided approaches.
Decline in Diagnostic Use of ERCP
The diagnostic application of ERCP has fallen sharply in recent years due to concerns over procedural risk. Diagnostic ERCP carries a small but significant risk of complications, including pancreatitis, infection, and bleeding.
The emergence of non-invasive alternatives such as magnetic resonance cholangiopancreatography (MRCP) and endoscopic ultrasound (EUS) has provided clinicians with effective imaging options that avoid these risks. As a result, diagnostic ERCP volumes have declined, shifting utilization toward therapeutic indications.
While this transition supports the growth of therapeutic devices like sphincterotomes and stents, it limits overall procedure expansion and caps market growth potential in some regions.
Price Competition
Competitive pricing pressures are moderating value growth in several ERCP subsegments. In particular, biliary and pancreatic stent markets have seen increasing competition from lower-cost manufacturers in South Korea and China. These suppliers have captured share in cost-sensitive markets such as Europe by offering stents with comparable quality at reduced prices.
Although these pressures are less severe than in other endoscopy markets, they continue to apply downward pressure on ASPs and restrict revenue growth, particularly in the stent and cannula categories.
Market Coverage and Data Scope
Quantitative Coverage
Market size, shares, and forecasts
Growth rates, units sold, and average selling prices
Qualitative Coverage
Market growth trends and limiters
Competitive analysis and SWOT for top competitors
Mergers and acquisitions, company profiles, and product portfolios
FDA recalls and disruptive technology analysis
Disease overview and procedure trends impacting demand
Time Frame
Base year: 2025
Forecasts: 2026–2032
Historical data: 2022–2024
Data Sources
Primary interviews with endoscopists and market executives, regulatory filings, government and hospital data, import and export databases, and iData Research’s internal database.
Method Note
Revenue is modeled from units multiplied by ASP, validated with procedural and utilization data and cross-checked with regional replacement and growth assumptions.
Markets Covered and Segmentation
Endoscopic Retrograde Cholangiopancreatography (ERCP) Device Market – Further Segmented Into:
Sphincterotome
Biliary Stone Removal Balloon
Biliary Stone Removal Basket
Biliary Dilation Balloon
Biliary and Pancreatic Stent
Biliary Lithotripter
ERCP Guidewire
ERCP Cannula
Competitive Analysis
Boston Scientific is the dominant global competitor in the ERCP device market. Since acquiring Xlumena and its AXIOS lumen-apposing covered-metal stent in 2015, the company has achieved strong growth in therapeutic applications. These stents are designed for transgastric or transduodenal drainage of symptomatic pancreatic pseudocysts and walled-off necrosis under EUS guidance. Boston Scientific’s broad distribution network and established brand recognition support its leadership position across most ERCP product segments.
Olympus Corporation has established a strong foothold through its V-System short-wire platform, which has gained traction among physicians transitioning to short-wire procedures. Although a later entrant into the ERCP market, Olympus has leveraged its endoscopy portfolio to rapidly increase its market share, especially within the sphincterotome category.
Cook Medical remains one of the most diversified competitors in the ERCP space, offering a complete portfolio that includes guidewires, sphincterotomes, and lithotripters. The company benefits from long-standing clinical relationships and a reputation for reliable device performance. Growth within its sphincterotome and guidewire segments continues to reinforce its position as a key global supplier.
The ERCP market remains moderately concentrated, with these three companies controlling a majority of global share. Other regional manufacturers participate in specific niches or geographies, particularly in Asia-Pacific and Latin America.
Technology and Practice Trends
Short-wire systems are replacing long-wire techniques, improving procedural control and reducing reliance on assistant staff.
Single-use sphincterotomes and cannulation devices are gaining adoption as hospitals focus on infection prevention and workflow efficiency.
Drug-eluting and lumen-apposing stents are enabling advanced therapeutic interventions previously requiring surgery.
Digital imaging integration within ERCP suites is enhancing visualization and procedural accuracy.
Lithotripsy devices continue to evolve with improved energy delivery systems that shorten treatment times and improve fragmentation efficiency.
Training expansion through simulation and mentorship programs is increasing global access to advanced ERCP procedures.
Geography
This edition provides global coverage across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
Why This Report
Where are the largest and fastest-growing opportunities within the global ERCP device market
How will short-wire systems and therapeutic ERCP adoption influence market growth through 2032
What are the key risks and constraints, including price competition and the decline of diagnostic ERCP
Which technological advancements are driving product differentiation in stents, sphincterotomes, and guidewires
How do leading manufacturers Boston Scientific, Olympus, and Cook Medical compete across product categories and regions
What training and infrastructure trends are shaping adoption in emerging markets
The Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Device Market Report from iData Research answers these questions with procedure-aware models, pricing data, and company share analysis. Use it to quantify demand, support strategic planning, benchmark product performance, and identify future growth opportunities.
About iData Research
iData Research is a premium market intelligence firm headquartered in Canada with offices across North America and Europe.
Over the last 20 years, the company has specialized in device-level sizing, procedure models, pricing trends, and competitive share across MedTech.
Since 2005, iData has supported global OEMs, mid-market innovators, and investors with triangulated data based on units and ASPs, with country-level forecasts and analyst access across Europe, North America, Latin America, the Middle East, Africa, and APAC.
Reports are available with flexible licensing to fit commercial, strategy, and investment workflows
Executive Summary
The global endoscopic retrograde cholangiopancreatography (ERCP) device market was valued at over $1.9 billion in 2025. The market is projected to grow at a compound annual growth rate (CAGR) of 5.6%, reaching over $2.8 billion by 2032.
This report covers sphincterotomes, biliary stone removal balloons, biliary stone removal baskets, biliary dilation balloons, biliary and pancreatic stents, biliary lithotripters, ERCP guidewires, and ERCP cannulas.
It quantifies unit sales, average selling prices (ASPs), market values, and growth rates, and includes company shares, market drivers and limiters, recent mergers and acquisitions, and technology trends. The analysis incorporates historical data from 2022 to 2024 and forecasts through 2032.
The scope reflects how healthcare providers are adopting minimally invasive, therapeutic ERCP techniques and how ongoing product innovation, particularly short-wire systems and lumen-apposing stents, is improving procedural efficiency and patient outcomes.
Market Overview
Endoscopic retrograde cholangiopancreatography (ERCP) is a specialized endoscopic procedure used to diagnose and treat conditions of the biliary and pancreatic ducts. It combines endoscopic and fluoroscopic imaging to enable interventions such as sphincterotomy, stone extraction, and stent placement.
Over the past decade, the role of ERCP has evolved from a primarily diagnostic tool to a therapeutic intervention, supported by major advances in device design and procedural technique. This transformation has expanded the addressable market for ERCP devices and positioned the field as a cornerstone of minimally invasive gastrointestinal care.
Market growth is being driven by increasing procedure volumes in both developed and emerging regions. The rising global incidence of biliary obstruction, gallstones, and pancreatitis is fueling demand for ERCP interventions. As populations age and chronic liver diseases become more prevalent, procedure frequency continues to rise.
Technology innovation has been especially impactful in improving physician control and reducing complication rates. The introduction of short-wire systems allows for faster cannulation, enhanced device exchange, and more efficient workflow. These systems are now regarded as the new procedural standard in many high-volume centers.
Drug-eluting and lumen-apposing stent technologies are also expanding the therapeutic capabilities of ERCP, enabling the management of complex indications such as pancreatic fluid collections and walled-off necrosis under endoscopic ultrasound (EUS) guidance.
At the same time, certain segments such as ERCP cannulas are gradually being replaced by more advanced device types like sphincterotomes, limiting growth in specific categories. Despite these internal shifts, the ERCP device market remains positioned for sustained expansion through the next decade, reflecting both strong procedural momentum and the integration of therapeutic endoscopy into routine care.
Market Drivers
Sphincterotome Market
The shift toward therapeutic ERCP is a primary growth driver for the global market. As procedures increasingly focus on intervention rather than diagnosis, sphincterotomes are seeing rising demand. This segment represents one of the largest portions of the ERCP device market and will continue to influence overall growth through 2032.
Advancements in sphincterotome design, such as improved wire control and compatibility with short-wire systems, are further expanding utilization. As hospitals transition toward single-use accessories to reduce infection risk, this category’s contribution to overall market value is expected to strengthen.
Short-Wire Systems
The increasing use of short-wire systems is reshaping how ERCP procedures are performed. These systems provide physicians with greater procedural control and efficiency while reducing the need for an assistant during cannulation and device exchange.
Short-wire configurations are more expensive than traditional long-wire systems but offer clinical and operational advantages that justify the premium. Adoption is accelerating in both hospital and ambulatory endoscopy settings, where shorter procedure times improve throughput and reduce anesthesia exposure. As a result, short-wire systems are contributing to rising ASPs and overall revenue growth.
Physician Familiarity and Training
As endoscopists gain more experience and training in therapeutic ERCP, procedural confidence is improving. The rise in physician familiarity has directly translated into higher case volumes per practitioner. Medical societies and device manufacturers are expanding training programs, increasing comfort with advanced ERCP techniques such as sphincterotomy, stenting, and lithotripsy.
These trends are particularly important in emerging markets, where expanded access to training and fluoroscopy equipment is helping to increase the number of qualified providers capable of performing ERCP safely and effectively.
Market Limiters
Cannula Market Decline
The ERCP cannula segment is being steadily replaced by sphincterotome-based techniques. Cannulas once represented a standard access tool but are now losing share as more efficient alternatives become the norm. As a result, unit sales have stagnated and average selling prices have declined for several years. Manufacturers have reduced pricing to remain competitive, suppressing total market value growth.
This structural change is expected to continue until cannulas are fully phased out, reinforcing the dominance of sphincterotome-guided approaches.
Decline in Diagnostic Use of ERCP
The diagnostic application of ERCP has fallen sharply in recent years due to concerns over procedural risk. Diagnostic ERCP carries a small but significant risk of complications, including pancreatitis, infection, and bleeding.
The emergence of non-invasive alternatives such as magnetic resonance cholangiopancreatography (MRCP) and endoscopic ultrasound (EUS) has provided clinicians with effective imaging options that avoid these risks. As a result, diagnostic ERCP volumes have declined, shifting utilization toward therapeutic indications.
While this transition supports the growth of therapeutic devices like sphincterotomes and stents, it limits overall procedure expansion and caps market growth potential in some regions.
Price Competition
Competitive pricing pressures are moderating value growth in several ERCP subsegments. In particular, biliary and pancreatic stent markets have seen increasing competition from lower-cost manufacturers in South Korea and China. These suppliers have captured share in cost-sensitive markets such as Europe by offering stents with comparable quality at reduced prices.
Although these pressures are less severe than in other endoscopy markets, they continue to apply downward pressure on ASPs and restrict revenue growth, particularly in the stent and cannula categories.
Market Coverage and Data Scope
Quantitative Coverage
Market size, shares, and forecasts
Growth rates, units sold, and average selling prices
Qualitative Coverage
Market growth trends and limiters
Competitive analysis and SWOT for top competitors
Mergers and acquisitions, company profiles, and product portfolios
FDA recalls and disruptive technology analysis
Disease overview and procedure trends impacting demand
Time Frame
Base year: 2025
Forecasts: 2026–2032
Historical data: 2022–2024
Data Sources
Primary interviews with endoscopists and market executives, regulatory filings, government and hospital data, import and export databases, and iData Research’s internal database.
Method Note
Revenue is modeled from units multiplied by ASP, validated with procedural and utilization data and cross-checked with regional replacement and growth assumptions.
Markets Covered and Segmentation
Endoscopic Retrograde Cholangiopancreatography (ERCP) Device Market – Further Segmented Into:
Sphincterotome
Biliary Stone Removal Balloon
Biliary Stone Removal Basket
Biliary Dilation Balloon
Biliary and Pancreatic Stent
Biliary Lithotripter
ERCP Guidewire
ERCP Cannula
Competitive Analysis
Boston Scientific is the dominant global competitor in the ERCP device market. Since acquiring Xlumena and its AXIOS lumen-apposing covered-metal stent in 2015, the company has achieved strong growth in therapeutic applications. These stents are designed for transgastric or transduodenal drainage of symptomatic pancreatic pseudocysts and walled-off necrosis under EUS guidance. Boston Scientific’s broad distribution network and established brand recognition support its leadership position across most ERCP product segments.
Olympus Corporation has established a strong foothold through its V-System short-wire platform, which has gained traction among physicians transitioning to short-wire procedures. Although a later entrant into the ERCP market, Olympus has leveraged its endoscopy portfolio to rapidly increase its market share, especially within the sphincterotome category.
Cook Medical remains one of the most diversified competitors in the ERCP space, offering a complete portfolio that includes guidewires, sphincterotomes, and lithotripters. The company benefits from long-standing clinical relationships and a reputation for reliable device performance. Growth within its sphincterotome and guidewire segments continues to reinforce its position as a key global supplier.
The ERCP market remains moderately concentrated, with these three companies controlling a majority of global share. Other regional manufacturers participate in specific niches or geographies, particularly in Asia-Pacific and Latin America.
Technology and Practice Trends
Short-wire systems are replacing long-wire techniques, improving procedural control and reducing reliance on assistant staff.
Single-use sphincterotomes and cannulation devices are gaining adoption as hospitals focus on infection prevention and workflow efficiency.
Drug-eluting and lumen-apposing stents are enabling advanced therapeutic interventions previously requiring surgery.
Digital imaging integration within ERCP suites is enhancing visualization and procedural accuracy.
Lithotripsy devices continue to evolve with improved energy delivery systems that shorten treatment times and improve fragmentation efficiency.
Training expansion through simulation and mentorship programs is increasing global access to advanced ERCP procedures.
Geography
This edition provides global coverage across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
Why This Report
Where are the largest and fastest-growing opportunities within the global ERCP device market
How will short-wire systems and therapeutic ERCP adoption influence market growth through 2032
What are the key risks and constraints, including price competition and the decline of diagnostic ERCP
Which technological advancements are driving product differentiation in stents, sphincterotomes, and guidewires
How do leading manufacturers Boston Scientific, Olympus, and Cook Medical compete across product categories and regions
What training and infrastructure trends are shaping adoption in emerging markets
The Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Device Market Report from iData Research answers these questions with procedure-aware models, pricing data, and company share analysis. Use it to quantify demand, support strategic planning, benchmark product performance, and identify future growth opportunities.
About iData Research
iData Research is a premium market intelligence firm headquartered in Canada with offices across North America and Europe.
Over the last 20 years, the company has specialized in device-level sizing, procedure models, pricing trends, and competitive share across MedTech.
Since 2005, iData has supported global OEMs, mid-market innovators, and investors with triangulated data based on units and ASPs, with country-level forecasts and analyst access across Europe, North America, Latin America, the Middle East, Africa, and APAC.
Reports are available with flexible licensing to fit commercial, strategy, and investment workflows
Table of Contents
101 Pages
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
